3030-10-2

Basic information

• Product Name: 3-bromo-6-(carboxymethylamino)-2-chlorobenzoic acid
• Synonyms: 3-bromo-6-(carboxymethylamino)-2-chlorobenzoic acid
• CAS NO: 3030-10-2
• Molecular Formula: C₉H₇BrClNO₄
• Molecular Weight: 308.51318
• Mol File: 3030-10-2.mol
• Article Data: 2

Chemical Properties

• Melting Point: 169-171 °C (decomp)
• Boiling Point: 543.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.919±0.06 g/cm3(Predicted)
• PKA: 2.01±0.50(Predicted)
• CAS DataBase Reference: 3-bromo-6-(carboxymethylamino)-2-chlorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-6-(carboxymethylamino)-2-chlorobenzoic acid(3030-10-2)
• EPA Substance Registry System: 3-bromo-6-(carboxymethylamino)-2-chlorobenzoic acid(3030-10-2)

Safety Data

• Hazardous Substances Data: 3030-10-2(Hazardous Substances Data)

Upstream product

• 729597-47-1 N-(3-chloro-2-carboxy-phenyl)glycine 

Downstream Products

• 3030-06-6 1-acetyl-5-bromo-4-chloro-3-indolyl acetate 

Relevant articles and documents

Halogenated Phenols for Diagnostics, Antioxidant Protection and Drug Delivery

The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided.